Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVAX Pancreas Vaccine and CRS-207 in Metastatic Pancreatic Cancer
NCT01417000Phase 2Completed
- Sponsor
- Aduro Biotech, Inc.
- Start
- Sep 2011
- Primary completion
- Oct 2016
- Modality
- Oncolytic Viruses, Cell Therapies, Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of CRS-207 in pancreatic adenocarcinoma (PDAC), sponsored by Aduro Biotech, Inc.. Started Sep 2011; status: completed.
02
Drugs
CRS-207
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01417000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01417000.